EUVIMEDEUVIMED entdecken
Crossref

1726-P: Baseline Clinical and Proteomic Predictors of Glycemic Deterioration in SELECT

FERNANDO PALLUZZI, ILDIKO LINGVAY, KRISTINE FÆRCH, STEVEN KAHN, ALEJANDRO AGUAYO OROZCO, ANETTE GJESING, DYLAN M. BELMONT-RAUSCH, HANAN AMADID, KAI X. LIM, KENG C. SOH, MARIA QUIROGA, MARIE S. OSTENFELD und 3 weitere

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1726-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von FERNANDO PALLUZZI und 14 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: This post hoc analysis identified patients (pts) at high risk of glycemic progression (GP) using baseline (BL) clinical and proteomic data and evaluated their risk of major adverse cardiovascular events (MACE).

Methods

Pts receiving placebo (n=6578) in SELECT with complete 2-yr HbA1c profiles and BL proteomics were included. Pts receiving glucose-lowering rescue therapy during the 2-yr period were defined as clinical progressors (CP). Temporal clustering (TC) identified HbA1c (%) trajectories in the remaining pts. A validated random forest classifier identified BL clinical and proteomic factors predicting HbA1c progression. High-power predictive proteins were chosen. MACE risk was evaluated.

Results

TC revealed 3 clusters with stable glycemia and 1 with metabolic progression (MP) (Fig. A). Four BL variables (HbA1c %, leptin/adiponectin, TG/HDL, GGT) and 31 proteins (covering insulin sensitivity and liver function signaling pathways) identified pts with GP (CP + MP) from those without (Fig. B). The model predicted GP with 81.8% sensitivity, 87.1% specificity, and 84.9% precision, outperforming HbA1c cutoffs of 5.7% and 6.0% (94.4% and 66.3% sensitivity, 54.8% and 95.5% specificity). Pts with GP had higher odds of ≥1 MACE within 4 yrs vs all other clusters combined (OR = 1.63 [95% CI 1.36, 1.94]; p<0.001; Fig. C).

Conclusion

Pts with GP have increased MACE risk and can be identified with high precision using BL clinical and proteomic data. Disclosure F. Palluzzi: Employee; Current; Novo Nordisk A/S. I. Lingvay: Consultant; Current; Aadvarak Therapeutics, Abbvie, Alveus Therapeutics, Amgen, Antag Therapeutics, Arrowhead Pharmaceuticals, Astra Zeneca, Baim Institute, Bain Capital, Bayer, Betagenon AB, Bioio Inc., Biomea, Boehringe. Research Support; Current; Novo Nordisk A/S, Dexcom, Inc., Boehringer Ingelheim International GmbH. Consultant; Current; Eli Lilly, Genentech, Janssen/J&J, Juvena, Keros Therapeutic, Inc, Mediflix, Metsera, Neurocrine, Novo Nordisk, Penguin Bio, Pfizer, Regeneron, Response Pharmaceutical, Roche, Sanofi, Shionogi, Skye B, Tenvie, TERNS Pharma, Verdiva Bio, Viking Therapeutics, and Zealand Pharma. K. Færch: Employee; Ended; Novo Nordisk A/S. Board Member; Current; ChemoMetec. Stock/Shareholder; Current; Novo Nordisk A/S, ChemoMetec. S. Kahn: Advisory Panel; Current; AltPep, Amgen Inc., Congruence Therapeutics, Eli Lilly and Company, General Medicines, Kayothera, Merck & Co., Inc., Neurimmune, Novo Nordisk, Roche Pharmaceuticals. A. Aguayo Orozco: Employee; Current; Novo Nordisk. A. Gjesing: Employee; Current; Novo Nordisk. D.M. Belmont-Rausch: Employee; Current; Novo Nordisk A/S. Stock/Shareholder; Current; Viking Therapeutics. Stock/Shareholder; Ended; Madrigal Pharmaceuticals, Inc. H. Amadid: Employee; Current; Novo Nordisk A/S. Stock/Shareholder; Current; Novo Nordisk A/S. K.X. Lim: Employee; Current; Novo Nordisk A/S. Employee; Ended; Roche Pharmaceuticals. K.C. Soh: None. M. Quiroga: Employee; Current; Novo Nordisk. Stock/Shareholder; Current; Eli Lilly and Company, Genmab, Coloplast, Novo Nordisk. M.S. Ostenfeld: Employee; Current; Novo Nordisk. T.J. Bari: Employee; Current; Novo Nordisk A/S. Stock/Shareholder; Current; Novo Nordisk A/S. L. Bjerre Knudsen: Employee; Current; Novo Nordisk. N.B. Jorgensen: Employee; Current; Novo Nordisk A/S.

Zitieren

APA

PALLUZZI, F., LINGVAY, I., FÆRCH, K., KAHN, S., OROZCO, A. A., GJESING, A., BELMONT-RAUSCH, D. M., AMADID, H., LIM, K. X., SOH, K. C., QUIROGA, M., OSTENFELD, M. S., BARI, T. J., KNUDSEN, L. B., & JORGENSEN, N. B. (2026). 1726-P: Baseline Clinical and Proteomic Predictors of Glycemic Deterioration in SELECT. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1726-p

Vancouver

PALLUZZI F, LINGVAY I, FÆRCH K, KAHN S, OROZCO AA, GJESING A, et al. 1726-P: Baseline Clinical and Proteomic Predictors of Glycemic Deterioration in SELECT. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1726-p

BibTeX
@article{PALLUZZI2026,
  author = {PALLUZZI, FERNANDO and LINGVAY, ILDIKO and FÆRCH, KRISTINE and KAHN, STEVEN and OROZCO, ALEJANDRO AGUAYO and GJESING, ANETTE and BELMONT-RAUSCH, DYLAN M. and AMADID, HANAN and LIM, KAI X. and SOH, KENG C. and QUIROGA, MARIA and OSTENFELD, MARIE S. and BARI, TANVIR J. and KNUDSEN, LOTTE BJERRE and JORGENSEN, NILS B.},
  title = {1726-P: Baseline Clinical and Proteomic Predictors of Glycemic Deterioration in SELECT},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1726-p}
}
Kostenlos starten →